Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Retrospective study suggests high FCRL5 expression predicts poor treatment response and survival (median PFS 10.6 months vs. not reached, P = 0.002) and OS 13.2 months vs. not reached, P = 0.02)) in newly diagnosed myeloma.”
Title:High FCRL5 expression predicts poor treatment response and survival in newly diagnosed multiple myeloma: a retrospective study
Authors: Cainan Yu, Minghua Zhang, Jie Hui, Mengqing Zhu, Zengtian Sun, Yueyue Sun, Qian Sun, Zhiling Yan, Feng Zhu, Mingshan Niu, Depeng Li, Kunming Qi
You can read the Full Article on Frontiers in Oncology.
You can find other articles featuring Robert Orlowski on OncoDaily.
